Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ACP-104 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| 3 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| ACP-104 | DRUG | 200 mg, tablet, BID, 6 weeks |
| Placebo | DRUG | placebo, tablet BID, 6 weeks |
Inclusion Criteria: * Male or female; 18-60 years of age * The subject is physically healthy and medically stable. * The subject is able to provide informed consent * The subject has been diagnosed with schizophrenia for at least 1 year * Currently experiencing an acute episode of psychosis * The s...
ACP-104 is an investigational small molecule being developed for the treatment of schizophrenia. It is intended for acutely psychotic subjects with schizophrenia. The drug is currently in clinical development and has not been approved by the FDA.
ACP-104 is being developed by ACADIA Pharmaceuticals Inc., a biopharmaceutical company traded on the NASDAQ under the ticker ACAD. The company is conducting clinical research on this investigational drug for schizophrenia.
ACP-104 is in Phase 2 clinical development. It has completed a Phase 2 trial in acutely psychotic subjects with schizophrenia. The drug is investigational and has not received regulatory approval.
ACP-104 has been studied in one completed Phase 2 clinical trial, registered as NCT00490516. The trial was a randomized, double-blind, placebo-controlled study that enrolled 247 participants with schizophrenia in the United States.
ACP-104 is a distinct investigational drug developed by ACADIA Pharmaceuticals. It is being studied specifically for schizophrenia and is not marketed under any other name. Its mechanism of action has not been publicly disclosed in available trial information.